logo
Judge blocks Trump from cutting off gender-affirming care for federal inmates

Judge blocks Trump from cutting off gender-affirming care for federal inmates

CNN2 days ago

A federal judge on Tuesday ordered the Trump administration to continue providing gender-affirming medication for transgender inmates in federal prisons, dealing the latest blow to a multi-pronged effort by the president to pull back federal support for transgender health care.
'All parties seem to agree that the named plaintiffs do, in fact, need hormone therapy,' US District Judge Royce Lamberth wrote.
The preliminary injunction from Lamberth means that officials within the Bureau of Prisons cannot enforce guidance the agency's leadership issued earlier this year implementing President Donald Trump's order, which directed the agency to revise its policies to 'ensure that no Federal funds are expended for any medical procedure, treatment, or drug for the purpose of conforming an inmate's appearance to that of the opposite sex.'
Lamberth, an appointee of former President Ronald Reagan, said a group of transgender inmates who had been medically diagnosed with gender dysphoria and who challenged BOP's guidance implementing the president's order were likely to succeed on their claim that the agency violated federal rulemaking procedures. They will continue to receive drugs as prescribed, the judge said.
'Nothing in the thin record before the Court suggests that either the BOP or the President consciously took stock of—much less studied—the potentially debilitating effects that the new policies could have on transgender inmates before the implementing memoranda came into force,' Lamberth wrote in the 36-page ruling.
'The BOP may not arbitrarily deprive inmates of medications or other lifestyle accommodations that its own medical staff have deemed to be medically appropriate without considering he implications of that decision.'
Though the case was originally brought by three transgender inmates, Lamberth agreed to certify a class that consists of all federal inmates who are currently taking hormone therapy medication to treat their diagnosis of gender dysphoria, defined as the psychological distress an individual feels when their gender identity differs from their sex assigned at birth. Not every transgender individual has gender dysphoria.
There are currently about 1,000 people in federal custody who are diagnosed with gender dysphoria. Lamberth noted that the BOP was continuing to give more than 600 inmates their prescribed hormone therapy medications, despite Trump's prior order.
The Justice Department had tried to explain how the BOP was acting differently than the order said they should, Lamberth noted. A federal government lawyer at a recent hearing 'argued that the BOP's policy is to provide hormone therapy to inmates as necessary to address medical needs other than 'conforming an inmate's appearance to that of the opposite sex,' such as to ameliorate anxiety, depression, or suicidality associated with gender dysphoria. Therefore, they argue, the BOP has the authority to provide not just some relief, but the very relief that the plaintiffs sought in their Complaint—to wit, restoration of their hormone therapy.'
The case so far has highlighted the changing reality transgender inmates in federal prisons have faced since Trump took office in January.
Three different inmates — Alishea Kingdom, Solo Nichols and Jas Kapule — sued because they had been receiving hormone therapy where they were held and also had gained access to some supplies, such as underwear and cosmetics, that would enable them to accommodate their genders.
Kingdom is a transgender woman and was able to access feminine underwear and commissary items in addition to her hormone therapy medication, while Nichols and Kapule were able to have men's boxers and chest binders.
The BOP stopped Kingdom's hormone therapy in February, causing her anxiety, hopelessness, panic attacks and suicidal thoughts, she told the court.
But once she and the others filed the lawsuit, her hormone therapy was restored, Lamberth noted.
Nichols similarly had his testosterone injections reduced in February, until the BOP reversed course and restored the full dosage by the end of that month, court filings say.
Kapule never lost access to hormone therapy, according to the court records.
The judge in the case decided the three inmates would suffer irreparable harm if he didn't step in with this ruling, according to his opinion.
CNN has reached out to BOP for comment on the ruling.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novel Survey Effectively Screens Binge Eating in Diabetes
Novel Survey Effectively Screens Binge Eating in Diabetes

Medscape

timean hour ago

  • Medscape

Novel Survey Effectively Screens Binge Eating in Diabetes

A new diabetes-specific 10-item screening tool demonstrated excellent performance in detecting binge eating disorder in both patients with type 1 diabetes (T1D) and those with type 2 diabetes (T2D), showing strong associations with glycaemic control and mental health outcomes. METHODOLOGY: Although diabetes-specific screening for disordered eating behaviours is advised, the only available tool — the Diabetes Eating Problem Survey–Revised (DEPS-R) — is tailored for patients with T1D on rapid-acting insulin therapy, limiting its applicability across other diabetes types and treatment regimens. Researchers developed a 10-item non–insulin-specific version of the DEPS-R (DEPS-10) and evaluated its screening performance for binge eating disorder in 679 patients with T1D or T2D (mean age, 53.8 years) who had the disease for at least 1 year. The new survey assessed loss of control over eating, dietary and purging behaviours, and challenges in diabetes management. Researchers conducted a receiver operating characteristic curve analysis to test the screening performance of the DEPS-10 and compared it with those of the original DEPS-R and the Problem Areas In Diabetes (PAID) scale. TAKEAWAY: The point prevalence of binge eating disorder was 3.5% in the whole cohort, 2.9% in patients with T1D, and 4.3% in those with T2D. The DEPS-10 showed excellent screening performance for binge eating disorder (area under the curve [AUC], 0.92; P < .001), matching that of the DEPS-R (AUC, 0.92; P < .001) and surpassing that of the PAID scale (AUC, 0.82; P < .001). < .001), matching that of the DEPS-R (AUC, 0.92; < .001) and surpassing that of the PAID scale (AUC, 0.82; < .001). The DEPS-10 showed optimal sensitivity (87.5%) and specificity (86.9%) for detecting binge eating disorder at a cutoff score of greater than or equal to 15; participants with this cutoff score had higher body mass index and A1c level along with a greater psychological burden than those with scores below it. The stepwise approach of first screening with the PAID scale and then applying the DEPS-10 boosted specificity to 94%, compared with 87% when using the DEPS-10 alone and 67% when using the PAID scale alone. IN PRACTICE: "A two-step approach using the PAID followed by the DEPS-10 can be a feasible and time-efficient procedure in routine care," the authors wrote. SOURCE: This study was led by Laura Yvonne Klinker, Diabetes Center Mergentheim in Bad Mergentheim, Germany. It was published online on May 29, 2025, in Diabetic Medicine . LIMITATIONS: Higher DEPS-10 scores in one fifth of the participants may have been affected by glucagon-like peptide 1 therapy. Additionally, the relatively low positive predictive value of the DEPS-10 could have been attributed to its broader scope in detecting various disordered eating behaviours beyond binge eating disorder. DISCLOSURES: This study was funded by a grant from the German Center for Diabetes Research. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. References Credit Lead image: Anastasiia Torianyk/Dreamstime Medscape News UK © 2025 WebMD, LLC Cite this: Novel Survey Effectively Screens Binge Eating in Diabetes - Medscape - June 05, 2025.

How Hard Will Musk Fight Republicans' Budget Bill?
How Hard Will Musk Fight Republicans' Budget Bill?

New York Times

timean hour ago

  • New York Times

How Hard Will Musk Fight Republicans' Budget Bill?

Can Musk kill the budget bill? Elon Musk hasn't stopped criticizing the budget bill that he has called a 'disgusting abomination.' In fact, he appears to be just getting started. The debate in Washington now is how far Musk will go to try to defeat a bill that — by the assessment of Musk, several Republicans and now nonpartisan watchdogs — will vastly add to the federal debt. 'KILL THE BILL,' Musk posted on X on Wednesday, a message he urged followers to press with members of Congress. He has turned a majority of his feed into a stream of reposts of content criticizing the legislation and denouncing its effect on the nation's $36 trillion debt load. A string of assessments suggest that the bill will add to the debt. The most consequential, the nonpartisan Congressional Budget Office, estimated that the House version of the plan would add $2.4 trillion over the next decade, given both the roughly $3.8 trillion tax cut at its core and additional spending. (Other estimates are even higher, including the Penn Wharton Budget Model's: $2.8 trillion.) A Republican counter: Attack the messenger. The Trump administration advanced hard-to-believe claims about C.B.O. staff members' partisanship, and arguments that its analysis ignores projected economic growth. That said, a previous nonpartisan analysis of the House bill found that the tax cuts would generate nearly no additional economic growth, and even conservatives found the budget office's analysis credible. 'When all the models are in unison,' Erica York, the vice president for federal tax policy at the Tax Foundation, told The Times, 'it really doesn't make sense to triple down on the strategy to blame the scorekeeper.' Want all of The Times? Subscribe.

At Combs Trial, ‘Jane,' an Ex-Girlfriend, to Testify About Sex Abuse
At Combs Trial, ‘Jane,' an Ex-Girlfriend, to Testify About Sex Abuse

New York Times

timean hour ago

  • New York Times

At Combs Trial, ‘Jane,' an Ex-Girlfriend, to Testify About Sex Abuse

A second woman who prosecutors say was sex trafficked by Sean Combs is set to take the stand on Thursday at his federal trial in what is expected to be several days of testimony about drug-fueled sex marathons with male prostitutes known as 'freak-offs.' A judge has allowed the woman to testify anonymously, and she is being referred to in court by the pseudonym 'Jane.' She is the most significant witness since Casandra Ventura, Mr. Combs's on-and-off girlfriend of 11 years, whose allegations of physical and sexual abuse gave rise to the criminal case. Prosecutors have said that Jane's relationship with Mr. Combs mirrored the one he had with Ms. Ventura in many ways. Like Ms. Ventura, they have said, Jane was coerced into freak-offs through violence, financial control and threats related to videos of the sexual encounters, which they said Mr. Combs directed step by step. Unlike Ms. Ventura, who is a singer known as Cassie and a public celebrity, Jane's identity has not been revealed. The government has described Jane as a single mother who started spending time with Mr. Combs in 2020 and quickly fell in love with the music mogul, agreeing to participate in an initial freak-off to please him. 'Jane thought the first freak-off was a one-time, wild night,' Emily Johnson, one of the prosecutors, said at the start of the case. 'Jane was wrong.' Want all of The Times? Subscribe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store